跳至主要内容
临床试验/EUCTR2015-005753-12-GB
EUCTR2015-005753-12-GB进行中(未招募)1 期

Prospective, open-label, randomised pilot study to assess two possible routes of Faecal Microbiota Transplant (FMT) delivery in patients with ulcerative colitis. - STOP-Colitis Pilot Trial

niversity of Birmingham0 个研究点目标入组 30 人开始时间: 2018年8月2日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1)Over 18 and under 50 years of age
  • 2)regular morning bowel habits, which can be classified as Bristol stool chart type 2-5
  • 3)normal BMI (over 18.5 and under 25)
  • 4) presently be non-smokers (not smoked for the past 12 months)
  • 5) provide written informed consent
  • 1)Confirmed UC for at least 3 months from date of screening
  • 2) Age 12-70 years
  • 3) Partial Mayo score of between 4 and 8 despite stable 5ASA+/- thiopurine, methotrexate or no treatment
  • 4) Rectal bleeding subscore >0
  • 5) Written, signed informed consent and/or assent to the study.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 2
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 3

排除标准

  • GI history of:
  • -inflammatory bowel disease
  • -irritable bowel syndrome, idiopathic chronic constipation or chronic diarrhoea
  • -gastrointestinal malignancy or known polyposis
  • -celiac disease
  • -congenital or chronic liver disease
  • -per rectal bleeding
  • -major gastrointestinal surgery (eg gastric bypass)
  • AUTOIMMUNE history of systemic autoimmunity including:
  • -Connective tissue disease
  • -Thyroid disease
  • -Inflammatory arthritis
  • -Psoriasis
  • ATOPIC disease inc.
  • -Atopic dermatitis
  • -Eosinophilic disorders of the gastrointestinal tract
  • CHRONIC PAIN history inc.
  • -Chronic fatigue syndrome
  • -Fibromyalgia
  • CARDIOVASCULAR history of a cardiovascular or metabolic syndrome including:
  • -Diabetes (type 1 or type 2)
  • -High blood pressure
  • -High cholesterol
  • -High fasting glucose
  • -Heart disease (eg atherosclerosis, myocardial infarction, congestive heart failure)
  • NEUROLOGICAL history of neurological conditions including:
  • -Multiple Sclerosis
  • -Parkinson’s disease
  • -Alzheimer’s disease or dementia disorders
  • IMMUNOSUPPRESSION history of any major immunosuppressive mechanisms including:
  • -Calcineurin inhibitors
  • -Exogenous glucocorticoids
  • -Biological agents
  • -Anti-TNF factors
  • -Systemic chemotherapeutic anti-neoplastic agents
  • -Transplantation (eg solid organ, bone marrow, cornea etc)
  • MENTAL HEALTH AND WELL BEING history of having been diagnosed by a clinician with any of the following:
  • -Depression
  • -Bipolar disorder
  • -Schizophrenia or delusional disorder
  • -Eating disorder (eg anorexia and / or bulimia)
  • INFECTIOUS DISEASES
  • -Known to have HIV, HBV and/or HCV infection
  • -Known to have been exposed to HIV, HBV and/or HCV in the preceding 12 months
  • -Risk of Creutzfeldt-Jakob disease (CJD) or variant CJD
  • -Originate from or share sexual partners or have a parent who originates from areas with high-incidence Human T-cell Lymphotropic Virus eg Caribbean, Japan, South America and Africa.
  • -Positive microbiology testing for any of the pathogens described donor testing schedule
  • HIGH RISK ACTIVITIES FOR BLOODBORNE INFECTIONS
  • Engaged in any known high risk activities for blood-borne infections, including:
  • -Sexual contact with an individual with known or suspected HIV, AIDS and/or hepatitis
  • 另有 20 项未显示

研究者

相似试验